AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Italy Fines Apple €98.6 Million Over App Store Dominance 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
BUENA, N.J., Sept. 12, 2017 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Morgan Stanley 15th Annual Global Healthcare Conference. The Conference is taking place September 11-13, 2017 at the Grand Hyatt Hotel, New York, NY.
Jason Grenfell-Gardner, President and CEO and Jenniffer Collins, Chief Financial Officer of Teligent, Inc. will present on Tuesday, September 12, 2017 at 5:15 p.m. ET.
The presentation will be webcast and will be accessible online on the investors section of the Company's website at http://www.teligent.com. A replay will be available for 30 days.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Jenniffer Collins
Teligent, Inc.
(856) 697-4379
www.teligent.com
